新型免疫检查点在肿瘤治疗中的作用

doi:10.3760/cma.j.cn371439-20201119-00067

摘要/Abstract

摘要：

新型免疫检查点靶标如淋巴细胞激活基因-3、T细胞免疫球蛋白黏蛋白-3、T细胞免疫球蛋白和ITIM结构域、T细胞活化的V结构域免疫球蛋白、B7同系物3、B和T淋巴细胞弱化子在肿瘤治疗中具有重要作用,阻断它们可延缓肿瘤生长、增强免疫细胞抗肿瘤作用、提高宿主存活率,虽然这些新型免疫检查点处于研究的早期阶段,但随着科技的不断发展,其在肿瘤免疫治疗中将发挥越来越重要的作用。

关键词: 肿瘤, 治疗, 免疫检查点

Abstract:

New immune checkpoint targets such as lymphocyte activation gene-3, T-cell immunoglobulin mucin-3, T cell immunoglobulin and ITIM domain, V-domain immunoglobulin suppressor of T cell activation, B7 Homolog 3, B and T lymphocyte attenuator play an important role in tumor treatment. Blocking them can delay tumor growth, enhance the anti-tumor effect of immune cells, and improve the survival rate of the host. Although these new immune checkpoints are in the early stages of research, with the continuous development of science and technology, they will play an increasingly important role in tumor immunotherapy.

Key words: Neoplasms, Therapy, Immune checkpoint

吴远玲, 寿伟臻. 新型免疫检查点在肿瘤治疗中的作用[J]. 国际肿瘤学杂志, 2021, 48(6): 354-357.

Wu Yuanling, Shou Weizhen. Role of new immune checkpoints in tumor treatment[J]. Journal of International Oncology, 2021, 48(6): 354-357.

参考文献 42

[1]	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018,68(6):394-424. DOI: 10.3322/caac.21492. doi: 10.3322/caac.v68.6
[2]	Qin S, Xu L, Yi M, et al. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4[J]. Mol Cancer, 2019,18(1):155. DOI: 10.1186/s12943-019-1091-2. doi: 10.1186/s12943-019-1091-2
[3]	Perez-Santos M, Anaya-Ruiz M, Cebada J, et al. LAG-3 antagonists by cancer treatment: a patent review[J]. Expert Opin Ther Pat, 2019,29(8):643-651. DOI: 10.1080/13543776.2019.1642873. doi: 10.1080/13543776.2019.1642873 pmid: 31291131
[4]	Deng WW, Mao L, Yu GT, et al. LAG-3 confers poor prognosis and its blockade reshapes antitumor response in head and neck squamous cell carcinoma[J]. Oncoimmunology, 2016,5(11):e1239005. DOI: 10.1080/2162402X.2016.1239005. doi: 10.1080/2162402X.2016.1239005
[5]	Huang RY, Francois A, McGray AR, et al. Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer[J]. Oncoimmuno-logy, 2016,6(1):e1249561. DOI: 10.1080/2162402X.2016.1249561.
[6]	Wang J, Sanmamed MF, Datar I, et al. Fibrinogen-like protein 1 is a major immune inhibitory ligand of LAG-3[J]. Cell, 2019, 176(1-2): 334-347.e12. DOI: 10.1016/j.cell.2018.11.010. doi: S0092-8674(18)31502-2 pmid: 30580966
[7]	Du W, Yang M, Turner A, et al. TIM-3 as a target for cancer immunotherapy and mechanisms of action[J]. Int J Mol Sci, 2017,18(3):645. DOI: 10.3390/ijms18030645. doi: 10.3390/ijms18030645
[8]	Yuan J, Jiang B, Zhao H, et al. Prognostic implication of TIM-3 in clear cell renal cell carcinoma[J]. Neoplasma, 2014,61(1):35-40. pmid: 24195506
[9]	Yu M, Lu B, Liu Y, et al. Tim-3 is upregulated in human colorectal carcinoma and associated with tumor progression[J]. Mol Med Rep, 2017,15(2):689-695. DOI: 10.3892/mmr.2016.6065. doi: 10.3892/mmr.2016.6065
[10]	Cheng L, Ruan Z. Tim-3 and Tim-4 as the potential targets for antitumor therapy[J]. Hum Vaccin Immunother, 2015,11(10):2458-2462. DOI: 10.1080/21645515.2015.1056953. doi: 10.1080/21645515.2015.1056953 pmid: 26211834
[11]	Nakano M, Ito M, Tanaka R, et al. PD-1⁺ TIM-3⁺ T cells in malignant ascites predict prognosis of gastrointestinal cancer[J]. Cancer Sci, 2018,109(9):2986-2992. DOI: 10.1111/cas.13723. doi: 10.1111/cas.2018.109.issue-9
[12]	Zhang H, Song Y, Yang H, et al. Tumor cell-intrinsic Tim-3 promotes liver cancer via NF-κB/IL-6/STAT3 axis[J]. Oncogene, 2018,37(18):2456-2468. DOI: 10.1038/s41388-018-0140-4. doi: 10.1038/s41388-018-0140-4
[13]	Liu JF, Wu L, Yang LL, et al. Blockade of TIM3 relieves immunosuppression through reducing regulatory T cells in head and neck cancer[J]. J Exp Clin Cancer Res, 2018,37(1):44. DOI: 10.1186/s13046-018-0713-7. doi: 10.1186/s13046-018-0713-7
[14]	Xiao Y, Qing J, Li B, et al. TIM-3 participates in the invasion and metastasis of nasopharyngeal carcinoma via SMAD7/SMAD2/SNAIL1 axis-mediated epithelial-mesenchymal transition[J]. Onco Targets Ther, 2020,13:1993-2006. DOI: 10.2147/OTT.S237222. doi: 10.2147/OTT
[15]	Pu F, Chen F, Zhang Z, et al. TIM-3 expression and its association with overall survival in primary osteosarcoma[J]. Oncol Lett, 2019,18(5):5294-5300. DOI: 10.3892/ol.2019.10855.
[16]	Liu F, Liu Y, Chen Z. Tim-3 expression and its role in hepatocellular carcinoma[J]. J Hematol Oncol, 2018,11(1):126. DOI: 10.1186/s13045-018-0667-4. doi: 10.1186/s13045-018-0667-4
[17]	Mollica V, Di Nunno V, Gatto L, et al. Novel therapeutic approaches and targets currently under evaluation for renal cell carcinoma: waiting for the revolution[J]. Clin Drug Investig, 2019,39(6):503-519. DOI: 10.1007/s40261-019-00773-w. doi: 10.1007/s40261-019-00773-w
[18]	Cong Y, Cui Y, Zhu S, et al. Tim-3 promotes cell aggressiveness and paclitaxel resistance through NF-κB/STAT3 signalling pathway in breast cancer cells[J]. Chin J Cancer Res, 2020,32(5):564-579. DOI: 10.21147/j.issn.1000-9604.2020.05.02. doi: 10.21147/j.issn.1000-9604.2020.05.02
[19]	Dougall WC, Kurtulus S, Smyth MJ, et al. TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy[J]. Immunol Rev, 276(1):112-120. DOI: 10.1111/imr.12518. doi: 10.1111/imr.2017.276.issue-1
[20]	Zhang Q, Bi J, Zheng X, et al. Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity[J]. Nat Immunol, 2018,19(7):723-732. DOI: 10.1038/s41590-018-0132-0. doi: 10.1038/s41590-018-0132-0
[21]	Guillerey C, Harjunpää H, Carrié N, et al. TIGIT immune checkpoint blockade restores CD8⁺ T-cell immunity against multiple myeloma[J]. Blood, 2018,132(16):1689-1694. DOI: 10.1182/blood-2018-01-825265. doi: 10.1182/blood-2018-01-825265 pmid: 29986909
[22]	Duan X, Liu J, Cui J, et al. Expression of TIGIT/CD155 and correlations with clinical pathological features in human hepatocellular carcinoma[J]. Mol Med Rep, 2019,20(4):3773-3781. DOI: 10.3892/mmr.2019.10641.
[23]	Solomon BL, Garrido-Laguna I. TIGIT: a novel immunotherapy target moving from bench to bedside[J]. Cancer Immunol Immuno-ther, 2018,67(11):1659-1667. DOI: 10.1007/s00262-018-2246-5.
[24]	Le Mercier I, Chen W, Lines JL, et al. VISTA regulates the deve-lopment of protective antitumor immunity[J]. Cancer Res, 2014,74(7):1933-1944. DOI: 10.1158/0008-5472.CAN-13-1506. doi: 10.1158/0008-5472.CAN-13-1506
[25]	Blando J, Sharma A, Higa MG, et al. Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer[J]. Proc Natl Acad Sci U S A, 2019,116(5):1692-1697. DOI: 10.1073/pnas.1811067116. doi: 10.1073/pnas.1811067116
[26]	Zhang M, Pang HJ, Zhao W, et al. VISTA expression associated with CD8 confers a favorable immune microenvironment and better overall survival in hepatocellular carcinoma[J]. BMC Cancer, 2018,18(1):511. DOI: 10.1186/s12885-018-4435-1. doi: 10.1186/s12885-018-4435-1 pmid: 29720116
[27]	Zong L, Zhou Y, Zhang M, et al. VISTA expression is associated with a favorable prognosis in patients with high-grade serous ovarian cancer[J]. Cancer Immunol Immunother, 2020,69(1):33-42. DOI: 10.1007/s00262-019-02434-5. doi: 10.1007/s00262-019-02434-5
[28]	Dempke WCM, Fenchel K, Uciechowski P, et al. Second- and third-generation drugs for immuno-oncology treatment-the more the better?[J]. Eur J Cancer, 2017,74:55-72. DOI: 10.1016/j.ejca.2017.01.001. doi: 10.1016/j.ejca.2017.01.001
[29]	Musielak B, Kocik J, Skalniak L, et al. CA-170-a potent small-molecule PD-L1 inhibitor or not?[J]. Molecules, 2019,24(15):2804. DOI: 10.3390/molecules24152804. doi: 10.3390/molecules24152804
[30]	Castellanos JR, Purvis IJ, Labak CM, et al. B7-H3 role in the immune landscape of cancer[J]. Am J Clin Exp Immunol, 2017,6(4):66-75. pmid: 28695059
[31]	Jin Y, Zhang P, Li J, et al. B7-H3 in combination with regulatory T cell is associated with tumor progression in primary human non-small cell lung cancer[J]. Int J Clin Exp Pathol, 2015,8(11):13987-13995.
[32]	Li M, Zhang G, Zhang X, et al. Overexpression of B7-H3 in CD14⁺ monocytes is associated with renal cell carcinoma progression[J]. Med Oncol, 2014,31(12):349. DOI: 10.1007/s12032-014-0349-1. doi: 10.1007/s12032-014-0349-1
[33]	Bin Z, Guangbo Z, Yan G, et al. Overexpression of B7-H3 in CD133⁺ colorectal cancer cells is associated with cancer progression and survival in human patients[J]. J Surg Res, 2014,188(2):396-403. DOI: 10.1016/j.jss.2014.01.014. doi: 10.1016/j.jss.2014.01.014
[34]	Mao Y, Chen L, Wang F, et al. Cancer cell-expressed B7-H3 regulates the differentiation of tumor-associated macrophages in human colorectal carcinoma[J]. Oncol Lett, 2017,14(5):6177-6183. DOI: 10.3892/ol.2017.6935.
[35]	Liu C, Liu J, Wang J, et al. B7-H3 expression in ductal and lobular breast cancer and its association with IL-10[J]. Mol Med Rep, 2013,7(1):134-138. DOI: 10.3892/mmr.2012.1158. doi: 10.3892/mmr.2012.1158
[36]	Benzon B, Zhao SG, Haffner MC, et al. Correlation of B7-H3 with androgen receptor, immune pathways and poor outcome in prostate cancer: an expression-based analysis[J]. Prostate Cancer Prostatic Dis, 2017,20(1):28-35. DOI: 10.1038/pcan.2016.49. doi: 10.1038/pcan.2016.49
[37]	He L, Li Z. B7-H3 and its role in bone cancers[J]. Pathol Res Pract. 2019,215(6):152420. DOI: 10.1016/j.prp.2019.04.012. doi: 10.1016/j.prp.2019.04.012
[38]	Yang S, Wei W, Zhao Q. B7-H3, a checkpoint molecule, as a target for cancer immunotherapy[J]. Int J Biol Sci, 2020,16(11):1767-1773. DOI: 10.7150/ijbs.41105. doi: 10.7150/ijbs.41105
[39]	Davar D, Zarour HM. Immunological targets for immunotherapy: inhibitory T cell receptors[J]. Methods Mol Biol, 2020,2055:23-60. DOI: 10.1007/978-1-4939-9773-2_2.
[40]	Sedy JR, Gavrieli M, Potter KG, et al. B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator[J]. Nat Immunol, 2005,6(1):90-98. DOI: 10.1038/ni1144. doi: 10.1038/ni1144
[41]	Khadhraoui C, Kaabachi W, Tritar F, et al. Association of BTLA rs1982809 polymorphism with lung cancer risk in tunisian population[J]. Int J Immunogenet, 2020,47(6):554-562. DOI: 10.1111/iji.12491. doi: 10.1111/iji.v47.6
[42]	Chen YL, Lin HW, Chien CL, et al. BTLA blockade enhances cancer therapy by inhibiting IL-6/IL-10-induced CD19^high B lymphocytes[J]. J Immunother Cancer, 2019,7(1):313. DOI: 10.1186/s40425-019-0744-4. doi: 10.1186/s40425-019-0744-4